Results 231 to 240 of about 3,479,441 (357)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Erectile Dysfunction in Diabetic Patients. [PDF]

J Clin Med
Erinc O, Yilmaz O, Kaya TY, Algemi M, Akarsu M.   +4 more
europepmc   +1 more source

Facts and Misfacts on D‐Dimer Testing. Consensus Guidance From the Italian Society on Thrombosis and Hemostasis (SISET)

American Journal of Hematology, Volume 101, Issue 1, Page 97-109, January 2026.
ABSTRACT D‐dimer defines degradation products derived from the proteolysis mediated by plasmin on cross‐linked fibrin. The evidence‐based use of D‐dimer in some conditions has been consolidated. Currently, however, there is an entrenched prescription of D‐dimer testing to screen otherwise healthy subjects that may induce prescribing physicians to start
Armando Tripodi, Walter Ageno, Luca Barcella, Antonio Coppola, Marcello Di Nisio, Massimo Franchini, Monia Marchetti, Rossella Marcucci, Marco Marietta, Pasquale Pignatelli, Domenico Prisco, Valerio De Stefano   +11 more
wiley   +1 more source

Intravenous tissue plasminogen activator in functional stroke mimics. [PDF]

Postep Psychiatr Neurol
Kowalska MM, Michałowska MM, Leńska-Mieciek MM.   +2 more
europepmc   +1 more source

The physiological and pathological effects of sphingolipid metabolism and signaling in the central nervous system

Brain Pathology, Volume 36, Issue 1, January 2026.
Sphingolipids are vital components of cell membranes. Metabolic disruptions of sphingolipids, including ceramide and sphingosine‐1‐phosphate, are linked to neurological disorders. This article summarizes the classification, structure, and metabolic processes of sphingolipids, and the physiological and pathological effects of sphingolipid metabolism and
Tian Li, Haoying He, Ejuan Zhang, Fengjiao Hu, Zhuo Wang, Jian Xu, Mengliu Zeng, Biwen Peng   +7 more
wiley   +1 more source

A Multicenter, Open-Label Study to Assess the Safety of Nebulized Tissue Plasminogen Activator for the Acute Treatment of Pediatric Plastic Bronchitis: The PLATyPuS Trial. [PDF]

Pharmacotherapy
Stringer KA, Goldberg D, Chen S, Thrush P, Graham EM, Lubert A, Myers J, McLellan L, Flott T, Nasr S, Schumacher KR.   +10 more
europepmc   +1 more source

Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke

Nature Medicine, 2008
E. Su, L. Fredriksson, M. Geyer, E. Folestad, J. Cale, Johanna Andrae, Yamei Gao, K. Pietras, Kris M. Mann, M. Yepes, D. Strickland, C. Betsholtz, U. Eriksson, D. Lawrence   +13 more
semanticscholar   +1 more source

RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth

, 2006
Shakuntala Kondraganti, Christopher S. Gondi, Ian E. McCutcheon, Dzung Dinh, Meena Gujrati, Jasti Rao, William C. Olivero   +6 more
openalex   +2 more sources

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 16-26, January 2026.
Abstract Chronic kidney disease (CKD) is a serious complication occurring in nearly one of three people with type 1 diabetes (T1D). Major therapeutic advances have been made in the management of CKD for people with type 2 diabetes (T2D), thereby improving their kidney, cardiovascular, and survival outcomes.
Katherine R. Tuttle, Linong Ji, Chantal Mathieu, Jonathan Rosen   +3 more
wiley   +1 more source

Hepatic AhR Activation by TCDD Induces Obesity and Steatosis via Hepatic Plasminogen Activator Inhibitor-1 (PAI-1). [PDF]

Int J Mol Sci
Oh SJ, Im S, Kang S, Lee AG, Lee BC, Pak YK.   +5 more
europepmc   +1 more source

Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK

, 2010
William M. Armstead, John Riley, J. Willis Kiessling, Douglas B. Cines, Abd Al‐Roof Higazi   +4 more
openalex   +2 more sources